Curated CRC research, accessible, accurate, actionable

The CRC Digest

Tuesday, September 15, 2026

Was this forwarded to you? Read on the web or subscribe free

IMPORTANT: The CRC Digest curates and summarizes publicly available research for informational and educational purposes only. Nothing in this newsletter constitutes medical advice, diagnosis, or treatment recommendation. The information provided should not be used as a substitute for professional medical advice. Always seek the guidance of your physician or other qualified health provider with any questions regarding a medical condition or treatment. Content is generated with AI assistance and reviewed by the editorial team. We are not medical professionals. Individual results, treatments, and outcomes vary.

CRC Research Update

• ◇ RESEARCH

  Early-onset and average-onset metastatic colorectal cancer share similar genomic landscapes

  An analysis of 1,892 patients found that major driver alterations. TP53, APC, and KRAS — occurred at comparable frequencies in metastatic colorectal cancer diagnosed before age 50 versus later, suggesting the diseases are genomically similar. (JCO Precision Oncology / The ASCO Post)

• ▪ SCREENING

  FIT-based screening linked to earlier colorectal cancer detection in Romania

  A retrospective study of 236 patients found that population-based screening using the fecal immunochemical test detected colorectal cancer at earlier stages compared to symptom-driven colonoscopy. (Cancers)

• ▪ SCREENING

  AI-assisted colonoscopy systems standardize polyp detection accuracy

  Computer-aided detection and diagnosis systems using deep learning convolutional neural networks reduce inter-operator variability in adenoma detection rates and help identify diminutive and morphologically subtle lesions. (Journal of Clinical Medicine)

• ◇ RESEARCH

  AI algorithm stratifies stage II/IIIA colorectal cancer recurrence risk from standard pathology slides

  HistoNav, a deep-learning algorithm analyzing H&E-stained tissue samples from 2,095 patients, identified low-, intermediate-, and high-risk groups with 5-year disease-specific survival rates of 93.2%, 84.3%, and 69.3%, respectively. (Cancers)

• ◇ RESEARCH

  Review examines why microsatellite-stable tumors resist immunotherapy

  A systematic review found that mismatch repair-proficient, microsatellite stable tumors remain resistant to immunotherapy due to low neoantigen load, defects in antigen presentation, and Wnt/β-catenin pathway activity that reduce immune recognition and T-cell infiltration. (Molecules)

Today's research spans genomic profiling in early-onset disease, AI applications in screening and pathology, and ongoing efforts to overcome immunotherapy resistance in microsatellite-stable tumors.